Aristopharma Ltd. has launched Resmetirom as first time in Bangladesh in the brand name of Livheal 80 mg & 100 mg Tablet. Resmetirom is the first and only FDA-approved oral therapy for NASH/MASH.
Resmetirom is a thyroid hormone receptor-beta (THR-β) agonist which is the first & only US FDA approved diseases specific oral therapy indicated for the treatment of NASH/MASH with fibrosis (stages F2 to F3). It works through multiple pathways and where it works directly in the liver by stimulating THR-β to improve critical hepatic processes and reduce fibrosis. Resmetirom stimulates THR-β signaling, regulating the expression of genes that improve critical processes in the liver, such as lipid metabolism and mitochondrial biogenesis. Thus, Resmetirom slows down the disease progression, reduces liver damage and improves liver health. Different clinical trials show that Resmetirom ensures broad response rate in NASH treatment & also ensures a favorable cardiovascular profile by reducing serum lipid profile.
FR
DE